Today's Rundown Dyne starts life with $50M, big biopharma names for muscle disease work As Brexit delayed, wannabe next PM wants to slash trial regulations AgomAb Therapeutics unveils itself with €21M, new leadership and Argenx collab [Sponsored] Biotech Companies Explore Alternative Strategies to Fund Growth Editas, BlueRock team up to develop off-the-shelf engineered cell therapies Bezos joins Gates-backed Alzheimer's diagnostics accelerator with new focus on digital biomarkers Featured Story | | | Wednesday, April 3, 2019 A new Atlas Venture-incubated startup looking to treat patients with rare forms of muscle diseases has got off a $50 million series A round with executives out of Amgen, Editas, Merck and Sarepta at the helm. |
|
|
Top Stories Wednesday, April 3, 2019 In the middle of a major democratic quagmire over when and how the U.K. should leave the EU, one man (and bookies’ favorite to be the next prime minister) is talking about cutting red tape surrounding clinical trials. Wednesday, April 3, 2019 AgomAb Therapeutics is coming out of stealth with a €21 million ($23.5 million) series A round to develop agonistic monoclonal antibodies—or “agomAbs”—that could potentially treat a variety of diseases. Monday, April 1, 2019 Deloitte discusses how biotech companies are exploring alternative strategies to fund growth including IPOs, collaborative arrangements, and share-based payment arrangements. Wednesday, April 3, 2019 Editas Medicine and BlueRock Therapeutics are pooling their knowledge to create new, off-the-shelf engineered cell therapies, with Editas working on cancer treatments and BlueRock focusing on neurology, cardiology and immunology. Wednesday, April 3, 2019 The Bill Gates-backed efforts to build better ways to diagnose and track Alzheimer’s disease have signed on another big-name supporter in Amazon founder Jeff Bezos. With the two richest people in the world behind it, the venture fund announced a new round focused on digital tools for the disease. Resources Sponsored by: USDM Life Sciences The year’s biggest compliance and technology trends in life sciences. Learn about the latest trends impacting the biotech, medical device and pharmaceutical industries. Sponsored by: Eurofins Discovery Learn how to utilize allosteric modulation to maximize its full potential in drug discovery programs. Download this white paper to learn more. Sponsored by: BioAnalytix, Inc. Discussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate. Sponsored by: PointCross Life Sciences Clinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma. Sponsored by: Unchained Labs Download this whitepaper to learn more! Sponsored by: Patheon, part of Thermo Fisher Scientific Is Flow Chemistry right for your API Development? Sponsored by: Veradigm Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care. Sponsored by: Outer Edge Technology Software end of life puts you at risk for data breaches, business disruption and liability. Support for Microsoft SQL Server 2008/2008 R2 and Windows Server 2008/2008 R2 ends on July 9, 2019 and January 14, 2020, respectively. Learn how you can turn these risks into a strategic business advantage. Sponsored by: AlphaSense From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve. Sponsored by: InterSystems Analytics using patients’ real-time longitudinal laboratory results, and claims data, yielded higher value information and new revenue streams for TriCore reference laboratories. Sponsored by: InterSystems Whitepaper on leveraging normalized real-world patient data to streamline clinical trials, reduce delays and lower costs. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Drug Development Immersion April 3-4, 2019 | Philadelphia, PA BioBasics: Biotech For The Non-Scientist May 8-9, 2019 | New York, NY Drug Development Immersion May 16-17, 2019 | Boston, MA 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA FierceBiotech Executive Breakfast at BIO 2019 – Getting Real: The Changing Tide on Real-World Evidence in Drug Development June 5, 2019 | Philadelphia, PA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 